Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset IOVA

Coverage 167,251 Raw stories ingested 22,003 rewritten in CS_CZ • 2 to rewrite (last 2 days).

Symbols 2,793 Assets with fetched stories

Cryptocurrencies BTC 7,371 ETH 4,875 XRP 3,294 SOL 2,999 HYPE 1,765 USDC 1,592

Stocks NVDA 1,796 SPCX 1,459 MU 1,331 MSFT 1,297 AAPL 1,079 TSLA 1,030

Commodities GOLD 556 SILVER 295 OIL 101 PLATINUM 14 PALLADIUM 4 COPPER 3

Forex EURUSD 500 GBPUSD 378 USDCAD 150 USDJPY 146 AUDUSD 100 USDCHF 63

2,195 with rewritten stories in CS_CZ • Hot assets ranked by fetched stories.

Agents 7 Live Pipeline agents

FMP Stock News Fetch every minute 25s ago
FMP Forex News Fetch every 5 min 25s ago
CoinGecko News Fetch every 5 min 2m ago
FIO Stock News Fetch every 10 min running now
Patria Stock News Fetch every 10 min 10m ago
Editorial rewrite Rewrite every minute 1m ago
Asset sync Assets every 1 hour 39m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

Category Source Ticker

Relevance

Clear

Details	Date	Content	Source	Relevance
	Saved 2026-08-20 17:55 20d ago Published 2026-08-20 13:14 20d ago	Iovance Biotherapeutics na 52týdenním maximu Iovance Biotherapeutics se dostala na 52týdenní maximum, přestože k pohybu nebyla žádná vlastní zpráva; od začátku roku akcie vzrostly o více než 200 %. IOVA Iovance Biotherapeutics	FMP Stock News	72
Original source text Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is trading at a 52-week high on Thursday, despite having no news to justify the move. Year to date, the stock has surged over 200%. • Iovance Biotherapeutics shares are testing new highs. Why did IOVA hit a new high? The momentum seems to come from breakthrough data from Moderna Inc. (NASDAQ:MRNA) and Merck & Co Inc.‘s (NYSE:MRK) individualized cancer therapy for advanced skin cancer. On Wednesday, the companies said that at a pre-planned interim analysis, the investigational combination delivered statistically significant and clinically meaningful improvements in recurrence-free survival and distant metastasis-free survival compared to standard Keytruda alone. Iovance’s Amtagvi Targets Advanced MelanomaInvestors should note that in February 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Iovance’s Amtagvi (lifileucel), a one-time tumor-infiltrating lymphocyte (TIL) therapy. Read Next It is derived from a patient’s surgically removed tumor, expanded in a lab, and then reinfused into patients. Indication covers adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. Iovance is also conducting TILVANCE-301, a Phase 3 trial to confirm clinical benefit. Moderna/Merck’s intismeran autogene is an mRNA-based individualized neoantigen therapy (INT) designed specifically for each patient based on the unique set of mutations within their tumor to train and activate the immune system to recognize and fight cancer. Iovance Reports Early Soft-Tissue Sarcoma DataIn February, Iovance shared positive early data from a pilot clinical trial for its TIL cell therapy in advanced soft-tissue sarcomas. Among the first six evaluable patients treated with lifileucel monotherapy, the trial showed a 50% confirmed objective response rate. Most recently, the cancer drug company reported a second-quarter loss of 11 cents per share, beating the consensus loss of 14 cents per share. Sales reached $99.313 million, beating the consensus of $87.832 million. U.S. Amtagvi revenue reached approximately $91 million. Iovance Biotherapeutics reaffirmed fiscal 2026 sales guidance of $350 million-$370 million versus the consensus of $362.083 million. Analysts Raise Price ForecastsUBS maintains Iovance Biotherapeutics with a Neutral rating and raises the price target from $4 to $7. Mizuho reaffirms the Outperform rating for IOVA stock and raises the price target from $10 to $11. IOVA Stock Price Activity: Iovance Biotherapeutics shares were up 9.64% at $8.76 at the time of publication on Thursday, according to Benzinga Pro data. Read Next Image via Shutterstock/ Aunt Spray © 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
	Saved 2026-08-10 21:30 30d ago Published 2026-08-10 15:29 30d ago	Iovance hlásí růst tržeb a nové 52týdenní maximum akcií Iovance Biotherapeutics oznámila za 2. čtvrtletí tržby ve výši 99,3 milionu USD, což je meziročně o 66 % více, a čistá ztráta klesla na 47,3 milionu USD. Akcie zároveň dosáhly nového 52týdenního maxima. IOVA Iovance Biotherapeutics	FMP Stock News	78
Original source text Shares of biopharmaceutical company Iovance Biotherapeutics (IOVA +0.95%) have been skyrocketing lately. The California-based business reported earnings recently, which pleased investors, and that's putting it lightly, as the stock also hit a new 52-week high. What's gotten investors so bullish on the healthcare stock, and is now a good time to buy it? Image source: Getty Images. Amtagvi drives significant sales growth for Iovance in Q2 On Aug. 6, Iovance released its second-quarter earnings numbers, which showed strong growth for its promising cancer treatment, Amtagvi (lifileucel). The company's revenue for the June quarter totaled $99.3 million, which was an increase of 66% from the prior-year period. The lion's share of the company's revenue comes from Amtagvi, which was responsible for $91 million. The Food and Drug Administration approved Amtagvi in early 2024 as a treatment for unresectable or metastatic melanoma. It has the potential to be a blockbuster for Iovance, as it may bring in more than $1 billion in revenue at its peak. However, how much it generates will depend on its approval for other indications. In addition to generating significant revenue growth this past quarter, the company also drastically reduced its losses during the period. Iovance's net loss came in at $47.3 million, which was less than half the $111.7 million loss it incurred in the same period last year. As Amtagvi continues to reach more patients and sales grow, there is hope that the business may have a path to profitability, which would make the stock a more attractive investment option for more risk-averse investors. Today's Change ( 0.95 %) $ 0.06 Current Price $ 6.40 Can Iovance's stock soar higher this year? Although Iovance's stock has been red hot of late, I think it can still rise higher. It's down more than 70% over the past five years, and now, with the business having an approved treatment and significant revenue to show for, it's not nearly as risky an investment as it was in the past. And with terrific margins, there's reason to be optimistic that it may get to breakeven in the future. The stock may even become an attractive acquisition target for a larger healthcare company, given its modest market cap of around $3 billion. There will inevitably be some risk with the stock because of its lack of profitability, but with some tremendous progress and positive signs around Iovance, I wouldn't be surprised if it were to rise a whole lot higher in the long run. This can be an excellent growth stock for investors who are comfortable taking on some risk and uncertainty.
	Saved 2026-08-06 16:27 1mo ago Published 2026-08-06 10:51 1mo ago	Iovance Biotherapeutics snížila ztrátu a překonala odhady výnosů Iovance Biotherapeutics vykázala ve 2. čtvrtletí ztrátu 0,11 USD na akcii, méně než čekal trh, a výnosy 99,31 milionu USD překonaly odhad o 13,73 %. IOVA Iovance Biotherapeutics	FMP Stock News	72
Original source text Iovance Biotherapeutics (IOVA - Free Report) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +35.29%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.19 per share when it actually produced a loss of $0.19, delivering no surprise. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Iovance Biotherapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $99.31 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 13.73%. This compares to year-ago revenues of $59.95 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Iovance Biotherapeutics shares have added about 59% since the beginning of the year versus the S&P 500's gain of 12.8%. What's Next for Iovance Biotherapeutics?While Iovance Biotherapeutics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Iovance Biotherapeutics was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.15 on $93.41 million in revenues for the coming quarter and -$0.60 on $359.12 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, ADC Therapeutics SA (ADCT - Free Report) , is yet to report results for the quarter ended June 2026. This company is expected to post quarterly loss of $0.19 per share in its upcoming report, which represents a year-over-year change of +62%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. ADC Therapeutics SA's revenues are expected to be $20.15 million, up 7% from the year-ago quarter.
	Saved 2026-07-09 05:12 2mo ago Published 2026-07-08 18:45 2mo ago	Iovance letos posílila o 74 %, tržby vzrostly o 45 % Iovance Biotherapeutics letos posílila o 74 % a její tržby v 1. čtvrtletí vzrostly meziročně o 45 % na 71,4 milionu USD. Akcie ale zůstává vysoce riziková kvůli regulačním a výrobním překážkám. IOVA Iovance Biotherapeutics	FMP Stock News	78
Original source text After several years of underperforming the market, Iovance Biotherapeutics (IOVA 1.61%) is finally bouncing back. The biotech company's shares have soared 74% this year. However, the stock still looks pretty cheap -- it is trading for just under $5 apiece. And for what it's worth, several Wall Street analysts think it could rise even more. Its average price target (according to Yahoo! Finance) is $8.80. Should investors rush to buy the company's shares? Image source: The Motley Fool. A high-risk, high-reward play Iovance Biotherapeutics developed Amtagvi, an approved medicine for treating melanoma. Amtagvi is manufactured from patients' own cancer-fighting cells, which are harvested, grown in a lab, and then reinserted back into the patient. Amtagvi's sales are growing at a good clip. In the first quarter, Iovance Biotherapeutics' revenue (mostly from this product) increased 45% year over year to $71.4 million. Meanwhile, Iovance Biotherapeutics is making progress in regions outside the U.S. It earned approval for Amtagvi in Canada last year, and could see the medicine's sales improve meaningfully as it ramps up commercial efforts in the country. Further, Iovance Biotherapeutics could obtain approval for Amtagvi in several other countries, including across the European Union. Launching the medicine in these regions would significantly expand its addressable opportunity, likely even more so than the Canadian market. Elsewhere, the company is making clinical progress. Iovance Biotherapeutics is developing Amtagvi for the treatment of endometrial cancer. The company also boasts several other pipeline candidates. Provided the biotech company can earn significant clinical wins over the next few years while also making solid commercial progress with Amtagvi, it could maintain the momentum it has had so far this year. Today's Change ( -1.61 %) $ -0.07 Current Price $ 4.28 However, several factors could derail Iovance Biotherapeutics' plans, including the very real risk of clinical or regulatory setbacks every drugmaker faces. It has already encountered several. For instance, Iovance Biotherapeutics announced earlier this year that it was withdrawing its regulatory application for Amtagvi in the United Kingdom due to "procedural reasons," although it said it would resubmit it promptly. Beyond potential regulatory roadblocks, there is a much bigger issue with the Company. The medicines it develops are complex to manufacture and administer. It takes about a month for Amtagvi to be manufactured after patients' cells have been harvested. And before receiving treatment, they have to undergo chemotherapy. Can Iovance Biotherapeutics eventually turn a profit, given that its therapies are so complex and expensive to administer? It's not clear that it can, and the company's bull case depends on a lot of things going right. Iovance Biotherapeutics may maintain its momentum if it continues to post strong financial results while eventually earning new approvals and label expansions. But the company is trading at a low price for a reason, and it could fall much further if it faces headwinds. So, Iovance Biotherapeutics is fairly risky, and only investors comfortable with volatility should consider initiating a position.